# Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

> **NCT01044069** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 93 (estimated)

## Conditions studied

- Leukemia
- Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** gene-modified T cells targeted

## Key facts

- **NCT ID:** NCT01044069
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2010-01-05
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 93 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01044069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01044069, "Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01044069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*